NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

HRTX

Heron Therapeutics Inc

Jul 03 • 04:00PM ET

2.20

Dollar change +0.05
Percentage change 2.33	%

Healthcare • Biotechnology • USA • NASD

Peers: JNJ PFE ABBV MRK BMY GILD LLY AMGN VRTX REGN

| Held by: VTI IWM VXF IWN SCHA VTWO IWC VHT ITOT IWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.06	Insider Own	0.95%	Shs Outstand	152.43M	Perf Week	1.85%
Market Cap	335.64M	Forward P/E	33.00	EPS next Y	0.07	Insider Trans	0.00%	Shs Float	151.11M	Perf Month	10.00%
Enterprise Value	462.22M	PEG	-	EPS next Q	-0.01	Inst Own	82.04%	Short Float	22.64%	Perf Quarter	-1.35%
Income	-7.79M	P/S	2.26	EPS this Y	80.56%	Inst Trans	12.31%	Short Ratio	21.27	Perf Half Y	45.70%
Sales	148.52M	P/B	-	EPS next Y	480.95%	ROA	-3.43%	Short Interest	34.21M	Perf YTD	43.79%
Book/sh	-0.19	P/C	6.62	EPS next 5Y	-	ROE	-	52W High	3.73 -41.02%	Perf Year	-36.60%
Cash/sh	0.33	P/FCF	-	EPS past 3/5Y	65.87% 48.68%	ROIC	-5.31%	52W Low	1.04 111.54%	Perf 3Y	-28.34%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	18.67% -0.23%	Gross Margin	73.97%	Volatility	7.12% 5.92%	Perf 5Y	-88.90%
Dividend TTM	-	EV/Sales	3.11	EPS Y/Y TTM	91.67%	Oper. Margin	-2.41%	ATR (14)	0.13	Perf 10Y	-92.51%
Dividend Ex-Date	-	Quick Ratio	1.76	Sales Y/Y TTM	12.43%	Profit Margin	-5.24%	RSI (14)	59.02	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.40	EPS Q/Q	164.11%	SMA20	5.72%	Beta	1.16	Target Price	6.25
Payout	-	Debt/Eq	-	Sales Q/Q	12.21%	SMA50	6.18%	Rel Volume	0.51	Prev Close	2.15
Employees	122	LT Debt/Eq	-	Earnings	May 06 BMO	SMA200	17.36%	Avg Volume	1.61M	Price	2.20
IPO	Aug 26, 1987	Option/Short	Yes / Yes	EPS/Sales Surpr.	261.29% 3.93%	Trades		Volume	823,589	Change	2.33%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-09-25	Initiated	H.C. Wainwright	Buy	$6
Jun-13-24	Initiated	Rodman & Renshaw	Buy	$7
Apr-23-24	Initiated	CapitalOne	Overweight	$6
Mar-13-24	Reiterated	Needham	Buy	$4 → $5
May-27-20	Initiated	Guggenheim	Buy	$24
Feb-20-20	Reiterated	Needham	Buy	$50 → $48
Jan-16-19	Reiterated	Needham	Buy	$66 → $64
Apr-05-18	Initiated	Evercore ISI	Outperform	$56
Mar-19-18	Reiterated	Mizuho	Buy	$28 → $35
Mar-01-18	Reiterated	Needham	Buy	$28 → $30
Jan-03-18	Initiated	Leerink Partners	Outperform	$22
Sep-27-17	Initiated	Northland Capital	Outperform	$40
Feb-27-17	Initiated	Needham	Buy	$28
Oct-26-16	Initiated	Aegis Capital	Buy
Sep-06-16	Resumed	Lake Street	Buy	$45
May-03-16	Initiated	Cantor Fitzgerald	Buy
Dec-10-15	Initiated	Lake Street	Buy	$45
Sep-23-15	Reiterated	Leerink Partners	Outperform	$38 → $57
Sep-02-15	Initiated	BofA/Merrill	Buy	$46
Aug-03-15	Reiterated	Brean Capital	Buy	$40 → $45

Show Previous Ratings

May-07-25 03:38PM	Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025 (Seeking Alpha) -6.61%
03:04AM	Heron Therapeutics Inc (HRTX) Q1 2025 Earnings Call Highlights: Record EBITDA and Significant ... (GuruFocus.com)
May-06-25 09:30AM	Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics (Zacks) +13.62%
08:55AM	Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates (Zacks)
07:53AM	Heron Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:45AM	Loading…
07:45AM	Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
07:30AM	Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI and APONVIE Patent Litigations (PR Newswire)
May-05-25 10:33AM	MTD Q1 Earnings Top Estimates, Sales Decline Y/Y, Shares Rise (Zacks) -7.79%
May-01-25 10:01AM	Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-29-25 10:01AM	Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-28-25 06:55PM	Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer (PR Newswire)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks)
Apr-23-25 09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Apr-22-25 04:05PM	Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025 (PR Newswire) +11.40%
10:15AM	Loading…
10:15AM	Best Momentum Stocks to Buy for April 22nd (Zacks)
09:40AM	Are Medical Stocks Lagging Encompass Health (EHC) This Year? (Zacks)
07:24AM	New Strong Buy Stocks for April 22nd (Zacks)
Mar-26-25 03:57PM	Is Heron Therapeutics, Inc. (HRTX) The Hot Biotech Stock Under $5? (InsiderMonkey)
Feb-28-25 02:08AM	Heron Therapeutics Inc (HRTX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) +20.49%
12:56AM	Q4 2024 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-25 09:30AM	Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +19.88%
07:54AM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:45AM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Feb-13-25 04:20PM	Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025 (PR Newswire) +7.88%
Dec-23-24 04:05PM	Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina (PR Newswire)
Dec-03-24 04:36PM	U.S. District Court Upholds Validity of CINVANTI Patents (PR Newswire) +38.98%
Nov-13-24 02:05AM	Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights (GuruFocus.com) -5.47%
Nov-12-24 10:00AM	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) -30.43%
09:10AM	Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:06AM	Loading…
08:06AM	Heron Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:55AM	Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance (PR Newswire)
Nov-07-24 09:15AM	Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Nov-04-24 05:00PM	Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors (PR Newswire)
Oct-29-24 04:05PM	Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 (PR Newswire) -7.33%
Oct-10-24 04:08PM	Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI, SUSTOL, and APONVIE as Alternatives During the Potential Shortage of Intravenous Fluids (PR Newswire)
Sep-25-24 08:00AM	Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire)
Sep-03-24 08:00AM	Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer (PR Newswire) -10.36%
Aug-06-24 07:30PM	Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -25.09%
06:45PM	Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:36PM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance (PR Newswire)
Jul-30-24 04:05PM	Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 (PR Newswire) +5.69%
Jul-15-24 08:00AM	Heron Therapeutics Announces the Inclusion of ZYNRELEF as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System (PR Newswire)
Jul-11-24 12:00PM	Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +8.88%
Jul-02-24 08:00AM	Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire) -21.04%
May-29-24 08:05AM	Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire)
May-21-24 12:00PM	What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now? (Zacks)
May-08-24 12:30PM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:10AM	Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Call Transcript Highlights: Significant ... (GuruFocus.com)
May-07-24 12:54PM	HRTX Stock Earnings: Heron Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:34AM	Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Overview: Surpasses Revenue Estimates (GuruFocus.com)
09:30AM	Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:05AM	Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:06AM	Heron Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Apr-30-24 10:01AM	Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know (Zacks) -7.20%
Apr-24-24 08:00AM	Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 (PR Newswire) -5.36%
Apr-11-24 04:05PM	Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City (PR Newswire) +7.69%
Mar-28-24 04:05PM	Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-13-24 09:19AM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call Transcript (Insider Monkey) +27.54%
07:04AM	Q4 2023 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-12-24 06:00PM	Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics (Zacks)
05:33PM	Heron Therapeutics Inc (HRTX) Exceeds Full-Year Revenue Guidance for 2023 (GuruFocus.com)
04:34PM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Mar-07-24 09:15AM	Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Feb-28-24 08:00AM	Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 (PR Newswire)
Feb-23-24 11:56AM	12 Best Rising Penny Stocks To Buy (Insider Monkey)
Feb-06-24 12:00PM	All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy (Zacks)
Jan-25-24 06:44AM	Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion (Zacks)
Jan-24-24 01:47PM	Heron Therapeutics' Non-Opioid, Post-Operative Pain Drug Approved For Use In Additional Orthopedic, Soft Tissue Procedures - FDA Gives Nod (Benzinga) +18.86%
Jan-23-24 08:00PM	Heron Therapeutics Announces FDA Approval of ZYNRELEF Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures (PR Newswire) -5.98%
Jan-15-24 04:51PM	The 3 Most Undervalued Biotech Stocks to Buy in January (InvestorPlace)
09:55AM	Heron Therapeutics (HRTX) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Jan-07-24 05:00PM	Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain (PR Newswire)
Dec-10-23 12:23PM	Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master (Associated Press Finance)
Dec-06-23 11:55AM	13 Hot Penny Stocks To Buy According to Hedge Funds (Insider Monkey)
Nov-28-23 07:33PM	Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth (InvestorPlace) -7.95% +7.00%
Nov-15-23 10:17AM	Heron Therapeutics Inc (HRTX) Raises 2023 Sales Guidance and Projects Positive EBITDA in 2024 (GuruFocus.com) +59.26%
08:51AM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:46AM	Q3 2023 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 06:00PM	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
04:17PM	Heron Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance (PR Newswire)
Nov-07-23 04:05PM	Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023 (PR Newswire) +6.88% -9.20%
Aug-24-23 09:29AM	11 Best Long-Term Penny Stocks to Buy Now (Insider Monkey)
Aug-15-23 01:30PM	Heron Therapeutics (HRTX) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) +10.93%
12:48PM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2023 Earnings Call Transcript (Insider Monkey)
09:47AM	Q2 2023 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 04:29PM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -6.79%
04:05PM	Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates (PR Newswire)
Aug-07-23 04:05PM	Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023 (PR Newswire)
10:50AM	Insiders Pour Millions Into These 2 Stocks Under $10 Heres Why Wall Street Thinks They Could Double (or More) (TipRanks)
Jul-26-23 01:30PM	Northland Capital Markets Institutional Investor Conference (ACCESSWIRE) +9.27%
Jul-24-23 09:02AM	Heron Therapeutics Announces Cost Reduction Plan and Restructuring (PR Newswire) +11.59%
09:00AM	Heron Therapeutics Announces $30 Million Private Placement Financing (PR Newswire)
Jun-23-23 04:05PM	Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer (PR Newswire) -6.61%
Jun-12-23 09:00AM	Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer (PR Newswire)
May-11-23 05:15PM	Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -8.98% -37.22%

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in Cary, NC.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HRTX

Heron Therapeutics Inc

Upgrade your FINVIZ experience